despite the finding of possible side effects in a large multicenter trial ( ugdp study ) demonstrating increased cardiovascular mortality during tolbutamide therapy , prescription of sulfonylureas has not declined in view of the inconclusive results of the study .
C0040374
tolbutamide
C0038766
sulfonylureas